Alvotech (ALVOW)

Market Cap	2.40B
Revenue (ttm)	491.98M
Net Income (ttm)	-231.86M
Shares Out	301.81M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	28.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Open	1.390
Previous Close	1.400
Day's Range	1.390 - 1.420
52-Week Range	1.390 - 1.420
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2025

About ALVOW

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVOW
• Website: https://www.alvotech.com

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.